Clover Health (CLOV) reported third-quarter earnings of $0.01 per share, against a consensus estimate calling for a $0.01 loss. That is a 200.0% earnings surprise and a swing from the $0.05 loss of a year ago. Revenue rose 52.9% year over year to $759.3 million, 1.7% above the $746.68 million consensus. Management also tightened full-year 2026 guidance toward the upper end for a second straight quarter. The headline beat is real but thin. The more consequential news was the PPO's 5-star rating for Payment Year 2028 and an early 2027 enrollment season that management described as strong. The quarter itself mattered less than what it signals for the next two years.
The quality of the beat deserves scrutiny. GAAP net income was $6.4 million, a $31 million improvement from last year's $24.4 million loss. However, the quarter included about $11 million of other income, about $4 million of which was a favorable investment valuation adjustment. Without that line, Clover would have posted an operating loss. A sharp drop in stock-based compensation, to $8.0 million from $26.1 million, also did much of the work in the GAAP improvement. Adjusted SG&A rose 60% and reached 15.0% of revenue, 70 basis points worse than a year ago, although the year-to-date ratio is still 120 basis points better. Earnings also fell sequentially. Adjusted EBITDA dropped to $16 million and GAAP net income to $6 million, from $41 million and $28 million in the second quarter. Management attributed that decline to expected seasonality.
The insurance book improved beneath those soft spots. The insurance benefits expense ratio improved 240 basis points to 91.1%, and consolidated gross profit jumped 77% to $130 million. Average Medicare Advantage membership grew 46% to 158,383. Growth is cooling modestly but remains exceptional. Third-quarter revenue growth of 52.9% compares with 56.7% for the first nine months, and membership growth of 46% compares with 49% year to date. Cash and investments climbed to $513 million, with no debt. Year-to-date operating cash flow reached $203 million, although a $116 million build in unpaid claims, a function of rapid growth, flattered that figure.
The call preserved a credible, and more assertive, growth story. Management's language moved from earlier "meet or exceed" caution to talk of a "clearly defined two-year opportunity." The low ends of guidance moved up again:
- revenue to $2.97 billion to $3.00 billion;
- adjusted EBITDA to $75 million to $85 million;
- GAAP net income to $25 million to $35 million.
That raise was smaller than the across-the-board lift in the second quarter. It also implies a fourth-quarter GAAP net loss of roughly $27 million to $37 million, reflecting seasonality and enrollment-season spending.
The new catalysts carry more weight. The flagship PPO, which management calls the largest five-star PPO contract in the U.S., now holds about 98% of members. The HMO earned 4.5 stars. Early 2027 enrollment is benefiting from Braven exiting New Jersey and from large national carriers retreating from $0-premium PPOs. Management also disclosed that cohorts moving from their second to their third year generate a gross profit step-up of about $85 per member per month, on top of the previously cited $70 step-up from year one to year two.
Bears have legitimate ammunition. The CMS appeal of the court-ordered Stars recalculation remains pending, and management declined to detail contingencies if it loses. Devoted Health is entering New Jersey. Outpatient utilization remains elevated, though within outlook. Contract concentration is extreme. Management also conceded that a large 2027 new-member cohort will dilute near-term earnings, and it offered no formal 2027 guidance.
The market setup is more complicated than the surprise implies. Shares entered the report at $4.29, down 12.3% from the $4.89 open following the August release. They sat 17.7% below the October 9 inter-earnings high of $5.21 and only 6.3% above the August low. The stock remains about 21% above its 200-day moving average of $3.55, so the longer-term uptrend is intact even after the quarter's fade. Investor sentiment of 0.27 was moderately positive heading into the print, reflecting constructive but not euphoric expectations. The internal trend readings are mixed, with momentum positive while AVWAP remains negative.
The bottom line is that Clover delivered a profitable, better-than-expected quarter whose GAAP earnings leaned on other income and lower stock compensation. The operating evidence that matters most points the right way: improving benefit ratios, upward guidance, a 5-star flagship PPO and favorable competitive dislocation heading into 2027. Investors are now underwriting a cohort-maturation earnings story rather than a single quarter. That story's biggest swing factors are the pending CMS appeal and the earnings drag from another large wave of new members.